Mr. Adams joined Cortigent as a consultant in November 2022, and was appointed Chief Executive Officer in March 2023.

Prior to joining Cortigent, Mr. Adams served in several executive roles, including CEO and COO at BioVie Inc., the company he founded in 2007. He led its successful up-listing to Nasdaq that raised substantial funding for operations. He has over 30 years of biopharmaceutical and device industry experience, including finance, M&A, technology commercialization, marketing, and sales support. At Searle Pharmaceuticals he was a member of the global launch team for the arthritis drug Celebrex, which generated billions of dollars in sales. He subsequently gained experience assisting companies with launching dozens of new drugs and medical devices.

Mr. Adams earned a BS from Cornell University and an MBA from the Tuck School of Business at Dartmouth.

Experience

• President & CEO (2023 - present)

  Cortigent, Inc.

Education

• MBA, Finance & Marketing (1987 - 1989)

  The Tuck School of Business at Dartmouth

• BS, Ag Economics (1981 - 1985)

  Cornell University